XBiotech Inc. (XBIT)
NASDAQ: XBIT
· Real-Time Price · USD
3.03
0.05 (1.68%)
At close: May 16, 2025, 3:59 PM
3.10
2.31%
After-hours: May 16, 2025, 04:28 PM EDT
XBiotech Revenue Breakdown
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|
| Manufacturing Revenue Revenue | 4.01M | 394K | 25.98M |
| Manufacturing Revenue Revenue Growth | +917.77% | -98.48% | n/a |
| Clinical Trial Service Revenue Revenue | n/a | 18M | 18M |
| Clinical Trial Service Revenue Revenue Growth | -100.00% | 0.00% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Nov 2, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.93M | 927K | 777K | 1.98M | 596K | 349K | 973K | 1.99M | 915K | 1.13M | 840K | 3.02M | 1.31M | 1.87M | 1.54M | 4.52M | 1.47M | 4.48M | 3.45M | 6.25M | 4.02M | 2.97M | 1.58M | 1.31M | 1.28M | 1.26M | 1.18M | 1.67M | 1.16M | 1.6M | 1.66M | 2.29M | 2.08M | 2.76M | 2.69M | 2.4M | 2.44M | 1.66M | 1.08M | 2.04M | 1.42M |
| Selling, General, and Administrative Revenue Growth | +108.31% | +19.31% | -60.80% | +232.55% | +70.77% | -64.13% | -51.15% | +117.70% | -18.95% | +34.40% | -72.21% | +130.06% | -29.58% | +21.09% | -65.88% | +208.26% | -67.31% | +30.03% | -44.81% | +55.26% | +35.27% | +88.47% | +20.18% | +2.74% | +1.03% | +7.66% | -29.72% | +44.51% | -27.69% | -3.79% | -27.35% | +9.89% | -24.42% | +2.64% | +11.92% | -1.52% | +46.92% | +53.09% | -46.89% | +43.49% | n/a |
| Research and Development Revenue | 11.62M | 7.82M | 7.13M | 12.98M | 9.82M | 7.8M | 7.55M | 11.27M | 6.23M | 7.32M | 7.01M | 10.39M | 6.82M | 8.78M | 5.6M | 9.25M | 4.63M | 3.46M | 2.35M | 2.56M | 1.16M | 10.34M | 4.53M | 4.69M | 4.53M | 4.84M | 3.94M | 3.95M | 2.99M | 5.91M | 4.93M | 7.4M | 8.19M | 13.69M | 9.77M | 11.22M | 7.81M | 10.41M | 9.73M | 4.38M | 6.78M |
| Research and Development Revenue Growth | +48.56% | +9.74% | -45.11% | +32.15% | +25.90% | +3.41% | -33.01% | +80.83% | -14.86% | +4.32% | -32.52% | +52.45% | -22.36% | +56.85% | -39.50% | +99.70% | +33.89% | +47.53% | -8.54% | +122.08% | -88.83% | +128.04% | -3.41% | +3.67% | -6.52% | +22.92% | -0.23% | +31.94% | -49.32% | +19.80% | -33.37% | -9.64% | -40.17% | +40.01% | -12.86% | +43.57% | -24.98% | +7.01% | +122.07% | -35.41% | n/a |